1st Edition
Handbook of Analysis of Oligonucleotides and Related Products
Purity Analysis and Impurities Determination by Reversed-Phase High- Performance Liquid Chromatography; H. Cramer, K. J. Finn, and E. Herzberg
Purity Analysis and Impurities Determination by AEX-HPLC; J. R. Thayer, V. Murugaiah, and Y. Wu
Purity Analysis and Molecular Weight Determination by Size Exclusion HPLC Analysis; M.F. Chan and I. Roymoulik
Analysis of Oligonucleotides by Liquid Chromatography—Mass Spectrometry; S. Pourshahian and S. M McCarthy
Sequence Determination and Confirmation by MS/M S and MALDI-TOF; Z. Timar
Tm Analysis of Oligonucleotides; H. Zhu and G. S. Srivatsa
Purity and Content Analysis of Oligonucleotides by Capillary Gel Electrophoresis; J.Carmody and B. Noll
Bioanalysis of Therapeutic Oligonucleotides Using Hybridization-Based Immunoassay Techniques; H. Legakis and S. Carriero
Oligonucleotide Assay and Potency; D. P. Michaud
Microbial Analysis: Endotoxin Testing; B. J. Markley
Analysis of Residual Solvents by Head Space Gas Chromatography; S. Countryman and J. V. Bonilla
Determination of Extinction Coefficient; V. Murugaiah
Structural Determination by NMR; M. L. DeRider, D. Brooks, and G. Burt
Infrared Analysis of Oligonucleotides; J. V. Bonilla
Stability Indicating Methods for Oligonucleotide Products; V. Murugaiah
Analysis by Hydrophilic Interaction Chromatography; R. N. Easter and P. A. Limbach
Determination of Base Composition; H. Aygün
Analysis of Metals in Oligonucleotides; M. P. Murphy
Regulatory Considerations for the Development of Oligonucleotide Therapeutics; G. S. Srivatsa
Biography
Dr. Jose V. Bonilla’s career has been dedicated to the introduction and implementation of cutting-edge analytical technologies such as LC-MS, high-speed gas chromatography, high-speed GPC, online GC, online HPLC, and online near-IR. He has extensive experience in the management of industrial and pharmaceutical analytical laboratories in compliance with regulatory requirements and is the author and coauthor of several peer-reviewed publications.
Dr. G. Susan Srivatsa
has more than 20 years of experience in the development of small molecules, proteins, peptides, and oligonucleotides as therapeutics. She has contributed to the successful development of more than 35 DNA and RNA oligonucleotide drug candidates through various stages of clinical development and has published widely in the area of oligonucleotide analysis in peer-reviewed journals.This is a unique resource for guiding the analysis of oligonucleotide-based drug products. No other single source provides such a comprehensive overview of the necessary analytical techniques that assess the qualitative characteristics of oligonucleotides intended for pharmaceutical use.
—Rachel R Chennault, Ph.D.(American College of Clinical Pharmacy), in Doody's Notes






